What is RxSight Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. RxSight's cash to debt ratio for the quarter that ended in Mar. 2024 was 49.70.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, RxSight could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for RxSight's Cash-to-Debt or its related term are showing as below:
RXST'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.36 Med: 3.45 Max: 49.7
Current: 49.7
During the past 5 years, RxSight's highest Cash to Debt Ratio was 49.70. The lowest was 1.36. And the median was 3.45.
RxSight Cash-to-Debt Historical Data
The historical data trend for RxSight's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
RxSight Cash-to-Debt Chart
|
RxSight Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
14.62 |
2.24 |
3.55 |
2.35 |
42.23 |
|
RxSight Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
3.45 |
6.28 |
39.60 |
42.23 |
49.70 |
Competitive Comparison of RxSight's Cash-to-Debt
For the Medical Devices subindustry, RxSight's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RxSight's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RxSight's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where RxSight's Cash-to-Debt falls into.
RxSight Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
RxSight's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
RxSight's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RxSight (RxSight) Business Description
Traded in Other Exchanges
N/A
Address
100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
Executives
| Ilya Goldshleger |
officer: Chief Operating Officer |
C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
| Eric Weinberg |
officer: Chief Commercial Officer |
C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
| Shweta Maniar |
director |
C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008 |
| Jesse Anderson Corley |
director |
C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
| Kurtz Ronald M Md |
director, officer: See Remarks |
C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
| Robert Keith Warner |
director |
C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
| Shelley B Thunen |
officer: Chief Financial Officer |
C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
| Bakker Juliet Tammenoms |
director |
LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
| Tamara Fountain |
director |
C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
| Robert J Palmisano |
director |
110 HARTWELL AVENUE, LEXINGTON MA 02173 |
| Link William J Phd |
director, 10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Julie Andrews |
director |
5677 AIRLINE ROAD, ARLINGTON TN 38002 |
| Rajeev M. Shah |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Peter Kolchinsky |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Ra Capital Management, L.p. |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
RxSight (RxSight) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RXST has been successfully added to your